ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy

BMC Cancer

Research Article

Jisuk Jo¹  Ghee Young Kwon²  Ji-Youn Sung²  Han Yong Choi³  Hyun Moo Lee³  Byong Chang Jeong³  Seong Soo Jeon³  Seong Il Seo³  Jong-Mu Sun⁴  Ho Yeong Lim⁴  Se Hoon Park⁴ 

[1] Cancer Research Institute, Research Institute for Future Medicine, Samsung Medical Center, Seoul, South Korea;Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea;Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea;Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea;

关键词: Bladder Cancer;    Adjuvant Chemotherapy;    Transitional Cell Carcinoma;    ERCC1 Expression;    Nucleotide Excision Repair Pathway;   

DOI  :  10.1186/1471-2407-12-187

 received in 2011-11-26, accepted in 2012-05-22,  发布年份 2012

来源: Springer

【 摘 要 】

BackgroundThe role of adjuvant chemotherapy and the value of molecular biomarkers in bladder cancer have not been determined. We aimed to assess the predictive and prognostic values of excision repair cross-complementation 1 (ERCC1) in identifying appropriate patients who may potentially benefit from adjuvant chemotherapy for bladder cancer.MethodsA retrospective analysis was performed on 93 patients with completely resected transitional cell carcinoma of the bladder. ERCC1 expression was assessed by immunohistochemistry. ERCC1 expression was analyzed in 57 patients treated with adjuvant gemcitabine plus cisplatin chemotherapy and 36 who were not treated.ResultsAmong 93 patients, ERCC1 expression was positive in 54 (58.1%) and negative in 39 (41.9%). ERCC1 positivity was significantly associated with longer survival (adjusted hazard ratio for death, 0.12, 95% confidence interval [CI] 0.014-0.99; P = 0.049) in the group without adjuvant chemotherapy while ERCC1 positivity was associated with shorter survival among patients who have received adjuvant chemotherapy (adjusted hazard ratio for death, 2.64; 95% CI 1.01-6.85; P = 0.047). Therefore, clinical benefit from adjuvant chemotherapy was associated with ERCC1 negativity as measured by overall survival (test for interaction, P = 0.034) and by disease-free survival (test for interaction, P = 0.20).ConclusionsAmong patients with completely resected transitional cell carcinoma of the bladder, those with ERCC1-negative tumors seemed to benefit more from adjuvant gemcitabine plus cisplatin chemotherapy than those with ERCC1-positive tumors. Future prospective, randomized studies are warranted to confirm our findings.

【 授权许可】

Unknown   
© Sun et al.; licensee BioMed Central Ltd. 2012. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.